Find an Article

Filter articles

Applied Filters

Showing 181 to 190 of 293 results

Protecting homeopathic treatments in Europe

EU07-06-2016André Guder

EPO case law suggests that inventions covering homeopathic medicines do not have to meet a higher bar of patentability than conventional medicaments, but it still must be shown that the claimed products lead to the alleged therapeutic effect. André Guder of Uexküll & Stolberg reports.

Biosimilars and biologics: the life sciences battleground


In an interview with LSIPR, Hans Sauer, deputy general counsel for intellectual property at the Biotechnology Innovation Organization, explains more about the big issues affecting it at the moment and how the trade association is responding.

Biotech in Birmingham: Alta Innovations’ story


Birmingham—Britain’s second city—with a leading university for research and development, allows biotech companies to enjoy the benefits of a cluster, as James Wilkie, CEO of Alta Innovations, the commercial spinout of the University of Birmingham, told LSIPR.

BIO 2016 session preview: “No Patent, No Cure”

EU05-06-2016Nathalie Moll

The biotech industry on both sides of the Atlantic is facing serious challenges in protecting its inventions, argues Nathalie Moll, secretary general of EuropaBio, which is organising a discussion on the topic at the 2016 BIO International Convention in San Francisco.

In or out? How UK and European politics are shaking IP all about

EU, UK02-06-2016Jane Wainwright and Tom Harding

With the UK set to decide on whether it wants to be in or out of Europe, Jane Wainwright and Tom Harding of Potter Clarkson examine how politics is shaping IP in Europe.

Supreme review: will SCOTUS take on Amgen v Sandoz?


In 2015 the US Federal Circuit resolved the biosimilars case of Amgen v Sandoz. But the parties did not stop there, meaning the Supreme Court could potentially review it. LSIPR looks at the consequences of a possible review.

Patent analysis: CRISPR technology in India

India, US19-05-2016Hemant Singh

It is likely that many patent applications directed to CRISPR technology will be filed in India, says Hemant Singh of Inttl Advocare, who analyses some of the early applications and the rules on patentability.

The world of gene editing patents

US05-05-2016Tony Trippe

CRISPR is only part of the gene editing story, and by studying the patents associated with all of the various methods, a much clearer picture of the entire field can be generated, says Tony Trippe, senior patent analyst for Thomson Reuters.

Taking shape: biosimilar rules in India

India14-04-2016Sameer Sah, Nisha Austine and Jahnvi Shah

The Indian government has invited public comments on draft regulatory guidelines for biosimilars, while patent law in this area has still to take shape. Sameer Sah, Nisha Austine and Jahnvi Shah of Khaitan & Co report.

Amgen v Sandoz: marketing exclusivity under the BPCIA

US07-04-2016Darryl Woo, Erin Ator Thomson, Janice Ta and Wendy Wang

The BPCIA requires a biosimilar applicant to notify the reference product sponsor of its drug no later than 180 days before the first commercial marketing date. Darryl Woo, Erin Ator Thomson, Janice Ta and Wendy Wang of Vinson & Elkins report on some of the pressing issues in this area.

Showing 181 to 190 of 293 results